Hereditary Prostate Cancer Panel, Sequencing and Deletion/Duplication

Casandra

Casandra Test Code AR81097Version 1 (DRAFT)

Performing Lab

Lab ARUP LaboratoriesLab Test ID 3005686CPT Code 81432

Hereditary Prostate Cancer Panel, Sequencing and Deletion/Duplication

Also known as: PROCAN NGS

Clinical Use

Order Test

Use

Pathogenic germline variants in multiple genes have been implicated in hereditary prostate cancer. Hereditary cancer syndromes are often characterized by early age of cancer onset (typically before 50 years of age) and multiple, multifocal, and/or similar cancers in a single individual or in closely related family members. Approximately 10% of prostate cancers are associated with a hereditary cause. Pathogenic germline variants in genes associated with hereditary prostate cancer are inherited in an autosomal dominant fashion. Some genes are also associated with autosomal recessive childhood cancer predisposition or other syndromes.

Special Instructions

Testing minors for adult-onset conditions is not recommended; testing will not be performed in minors without prior approval. Specimens from New York clients will be sent out to a New York state-approved laboratory. Informed consent for genetic testing is required for New York patients.

Limitations

A negative result does not exclude a heritable form of cancer. This test only detects variants within the coding regions and intron-exon boundaries of the targeted genes. Regulatory region variants and deep intronic variants will not be identified. Single exon deletions are reported but called at a lower sensitivity. Variants may not be identified due to technical limitations caused by the presence of pseudogenes, repetitive, or homologous regions. This test is not intended to detect low-level mosaic or somatic variants, gene conversion events, complex inversions, translocations, or mitochondrial DNA variants.

Test Details